Neurocrine Biosciences Inc (FRA:NB3)
€ 124.9 0.85 (0.69%) Market Cap: 12.98 Bil Enterprise Value: 12.33 Bil PE Ratio: 38.55 PB Ratio: 5.90 GF Score: 90/100

Neurocrine Biosciences Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 07:00PM GMT
Release Date Price: €90.64 (+0.38%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the 39th Annual JPMorgan Healthcare Conference. My name is Anupam Rama, I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is Neurocrine. And speaking on behalf of the company, we have CEO, Kevin Gorman.

(Operator Instructions) Kevin, why don't you take it away?

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Thank you, Anupam, and to JPMorgan, broadly, as always, I really appreciate the opportunity to speak here today. Laurie, next slide, please. As -- and the one after that, please. I'm going to come up with our safe harbor statement here. And because I will be making forward-looking statements.

Next slide, Laurie, please. I -- bear with me for a moment. There's something I wanted to say right from the very outset. I've been in this business for over 30 years. And I've got to say that in that time, there's never been a time that I feel

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot